Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.

NCT00232934 is registered in ClinicalTrials.gov with Gruppo Italiano per lo Studio del Mieloma Multiplo as lead sponsor.

NCT NCT00232934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00232934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.
Lead sponsor
Gruppo Italiano per lo Studio del Mieloma Multiplo
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2002
Completion date
November 30, 2014
Enrollment
400
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma